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Abstract
Background: Human papillomavirus high risk (HPV-HR) type 16 is a significant risk factor for head and neck
cancers (HNC) independent of tobacco and alcohol. The purpose of this study was to determine whether antibody
levels to the HPV-16 oncoproteins E6 and E7 measured in sera collected at baseline (BL) prior to treatment and at
two post-treatment follow-up (FU) visits were associated with HNC risk factors or prognosis.
Methods: Presence of antibodies to HPV-16 E6 and E7 was evaluated in 109 newly diagnosed HNC cases with BL
and FU blood samples, using the enzyme-linked immunosorbent assay (ELISA).
Results: HPV-16 E6 and/or E7 seropositive HNC cases were associated with higher risk in younger patients (≤ 55
years), more sexual partners (≥ 10), oropharyngeal cancer, worse stage at diagnosis, poorer grade, and nodal
involvement. Between BL and FU (median = 8.3 months), there were decreased antibody levels for seropositive E6
(73% vs. 27%, p = 0.02) and seropositive E7 patients (65% vs. 35%, p = 0.09) with 5% of BL E6 and 35% of BL E7
seropositive patients converting to negative status at FU. Overall mortality (OM) was significantly worse among BL
E6 seronegative patients than among BL seropositive patients (40.2% vs.13.6%, p = 0.01). There were no disease
specific (DS) deaths among BL E6 seropositive vs. 24% in BL E6 seronegative patients (p = 0.01). BL E7 seronegative
patients also had higher mortality than BL seropositive patients (OM: 38.2% vs. 20.0%, p = 0.04; DS: 22.5% vs. 5.6%,
p = 0.07).
Conclusion: These findings are the first to follow post-treatment OD levels of HPV-16 E6 and E7 in HNC and
suggest that these HPV antibodies may be potential prognostic markers of survival in HNC patients.
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Background
Human papillomavirus high risk (HPV-HR) types are
causally related to cervical carcinomas [1] and a signifi-
cant risk factor for approximately 26% of head and neck
cancers (HNC) independent of tobacco and alcohol
[2-7]. Survival and recurrence of HNC have not changed
significantly over the past 30 years in the United States
and Western Europe with recurrence remaining at
~30% [8]. There is recent evidence of better survival
and lower recurrence among those detected with HPV-
HR in tumors [9-12], suggesting that understanding
HPV-HR infection is essential to understanding the
prognosis of these tumors.
Several investigations have found concordance in
HPV-16 positivity in tumor tissue and the presence of
HPV specific antibodies in cervical cancer patients
[13-15] and in HNC patients [3,16,7]. Antibodies to
HPV-HR oncoproteins E6 and E7 are late markers for
HPV-associated carcinoma with antibody prevalence
increasing with clinical stage [17,18,15]. These tumors
show constitutively high-level E6/E7 expression due to
increased mRNA transcription and stability. Invasion of
the E6/E7-overexpressed tumor cells beyond the mucosa
brings them in tight contact with cells of the immune
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tation and the induction of E6/E7 antibodies.
Several studies of cervical cancer have shown an asso-
ciation between decreased antibody level during pre-/
post-treatment follow-up and better prognosis
[19,13,14]. The purpose of this study was to examine
changes in and impact of HPV antibody levels in HNC
patients at baseline before treatment and at two follow-
up periods after treatment to determine whether they
are predictive of clinical outcomes.
Materials and methods
Patient population and study design
Newly diagnosed, primary HNC cases of the oral cavity
(OC), oropharynx (OP), or larynx/hypopharynx (LH)
were recruited between 2000-2005 at the University of
Iowa Hospitals and Clinics, Department of Otolaryngol-
ogy. They were administered a University approved
Human Subjects Review consent form prior to interview
and the study was approved by the institutional review
b o a r d sa tb o t ht h eU n i v e r s i t yo fI o w aH o s p i t a l sa n d
Clinics and the Iowa City Veterans Affairs Medical Cen-
ter. All OC, OP, and LH sites as defined by the Ameri-
can Joint Commission on Cancer [20], excluding
nasopharynx, were included. All histologies were
included and subsequently combined because there were
no significant differences in results between cases with
squamous cell carcinoma (SCC, N = 102) and other his-
tologic types (n = 7): 1 adenocarcinoma, 1 adenoid cys-
tic carcinoma, 3 mucoepidermoid carcinoma, and 2
verrucous carcinomas. Cases included in this study (N =
109) had an initial baseline (BL) while 108 patients had
a first follow-up (FU1) and 69 patients had a second fol-
low-up (FU2) with blood samples available for evalua-
tion of anti-HPV antibodies over a 3-24 month period.
Participants completed a risk factor questionnaire with
information about demographics, sexual practices,
tobacco and alcohol use, medical history, and history of
HPV-related diseases and oral lesions. A medical form
was completed using clinical medical records, supple-
mented by additional questions to the patient. Data
included prior cancer history, cancer site, and
treatments.
Laboratory methods, serological assays, HPV detection
and typing
The procedures performed on these clinical samples
have been described previously [16]. Presence of IgG
antibodies to antigens derived from HPV-specific pro-
teins was evaluated using the enzyme-linked immuno-
sorbent assay (ELISA) and have been described
elsewhere [21]. Optical densities (OD) were recalculated
into OD ratios dividing by the respective cutoff value.
An OD ratio above 1.0 was considered positive. Changes
in OD values between BL and FU were determined by
comparing the last titration dilution from each visit
before the OD ratio reached 1.0, the HPV detection cut
off. DNA was extracted from deparaffinized tumor tis-
sue sections with a QIAGEN DNA Tissue Kit (QIA-
GEN, Valencia, CA) and is described in more detail
elsewhere [22]. All tumor tissue tested positive for the
b-globin and PCR amplification of the cellular DNA ver-
ified adequate DNA [23]. DNA was PCR-amplified with
MY09 and MY11 primers to detect HPV [24]. An ali-
quot of the PCR product of each HPV-negative speci-
men was hybridized by the dot blot method with
32P-
labeled probes for detection of HPV DNA. Positive sam-
ples underwent hemi-nested PCR-amplification with
MY09 and GP5+ primers [25]. DNA sequencing
(Applied Biosystems-PE, Foster City, CA) was used to
identify HPV types in comparison with GenBank
sequences using the BLAST program [26].
Statistical methods
The Wilcoxon rank sum test and a median test were
used to compare quantitative variables between groups
of patients. The chi-square or Fisher’s exact test was
used to compare categorical variables. Multiple logistic
regression models [27], adjusting for continuous age,
pack years and drinks per week, were used to estimate
the odds ratios (ORs) and 95% confidence intervals (CI)
for the association of baseline serology status with HNC
risk factors and clinical characteristics of the tumors.
For some variables with zero cells, ORs and CIs were
generated with logit methods, adding 0.5 to zero cells
and adjusting for categorical age (≤ 55 years vs. > 55
years), pack years (never, ≤ 30, > 30), and drinks per
week (never, ≤ 21, > 21).
Each HPV serology test was evaluated at baseline (BL),
defined as the time of diagnosis prior to any treatment,
FU1 (n = 108, mean time to first follow-up = 7.0
months), FU2 (n = 69, mean time to second follow-up =
11.7 months), and FU (n = 109, mean time to the final
follow-up (FU1 or FU2) = 10.1 months). Survival curves
were generated using Kaplan-Meier methods, while Cox
regression models were used to generate hazard ratios
(HR) and 95% confidence intervals (CI), adjusted for
continuous age and stage of disease (III/IV vs. I/II).
Additional adjustment variables such as nodal involve-
ment, tumor site, and grade could not be added to mod-
els because of the high correlation among these
variables and with disease stage. Gender, pack-years and
drinks per week were not associated with survival or
recurrence and thus were not included in the models.
All model variables met the proportion hazards assump-
tion except for a disease specific model with E6 status
because there were no deaths among the E6 seropositive
patients. All reported p-values were two-sided, except
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eses that the alternatives to a null finding would be
decreased OD values (results supported by published
cervical cancer research) [19,13,14]. Statistical analyses
were performed using SAS version 9.2 [28].
Results
Patient characteristics, risk factors, and anti-HPV antibody
response at baseline
Table 1 shows differences in patient risk factors and his-
topathologic characteristics by BL HPV serology status.
Among the 109 cases, the majority was male (61%) and
the average age was 59 years (range: 23-90 years). The
overall antibody prevalence of HPV-16 E6 was 20%,
HPV-16 E7 18%, and E6 and/or E7 24%. HPV-HR DNA
(28 HPV-16 and 2 HPV-33)was detected in 28% of
HNC tumors and the prevalence was significantly higher
in the OP compared to the OC, 70% versus 15% (p <
0.0001). There were no HPV-HR tumors in the LH.
Males, those ≤ 55 of age and patients with ≥ 10 life-
time sexual partners were more likely to be E6, E7, or
E6 and/or E7 seropositive. HNC patients with > 0/ ≤ 30
pack years had significantly higher ORs for seropositivity
compared to never users, whereas patients who reported
heavier alcohol drinking (> 21 drinks/week) had elevated
ORs compared to never drinkers. OP tumors were asso-
ciated with significantly elevated risks among those who
were seropositive to BL E6, E7 and E6 and/or E7 when
compared to OC or LH tumors. Stages III/IV vs. I/II,
poorly or undifferentiated vs. moderate well differen-
tiated tumors, and nodal involvement (yes vs. no) also
were associated with elevated levels of BL E6 or E7 anti-
bodies. Compared to HPV DNA negative tumor cases,
HPV-HR tumor cases showed significantly higher risks
for each HPV-16 specific BL E6 or E7 antibody. Of the
21 patients with HPV-HR tumors that were BL E6 and/
or E7 seropositive, 20 tumors were HPV-16 and one
was HPV-33. One HPV-33 DNA tumor positive case
w a sB LE 6a n d / o rE 7s e r o n e g a t i v ea n d5H P VD N A
negative patients were BL seropositive.
Table 2 exhibits BL median HPV antibody OD ratios
for risk factors and tumor characteristics at baseline
among patients who were BL E6 or E7 seropositive. For
each antibody group, there were no significant differ-
ences in median OD ratios by age and gender, although
males displayed higher medians compared to females.
There were non-significant higher median values for
patients with three or more lifetime sexual partners ver-
sus 0-2 partners. There were no differences between
never users and users of tobacco or alcohol within each
E6 and E7 group or within E6 and/or E7.
The median HPV OD ratio for BL E6 and/or E7 anti-
bodies (table 2) was elevated in the OP compared to the
OC (5.9 vs. 4.2, p = 0.10). Compared to earlier stage
disease, patients in stages III/IV had elevated medians
within E6 and within E7 and had significantly higher
medians for E6 and/or E7 (5.8 vs. 1.3, p = 0.008). Com-
pared to patients with tumor size T1-T2, those with T3-
T4 tumors had significantly higher OD medians for E6
antibodies (6.8 vs. 4.9 p = 0.05), but medians were simi-
lar for E7 antibodies and for the E6 and/or E7 group.
There were no median OD differences by grade for E6,
E7 and the E6 and/or E7 antibodies. The median OD in
patients with nodal involvement compared to those
without nodal involvement was elevated within E6 and
within E7 and was significantly higher for E6 and/or E7
(5.8 vs. 2.1, p = 0.04).
HPV antibody response at follow-up
Table 3 displays changes in the HPV OD ratios between
BL and FU1, FU2 and final FU among patients seroposi-
tive at BL. Not all patients had a second FU (n = 40). At
the last FU, over 72% of seropositive patients had a
decrease in the anti-E6 ratio (p = 0.02) and 65%
decreased in the anti-E7 ratio (p = 0.09). Although a
majority of patients displayed a decreased OD ratio at
the last FU, only 5% of E6 positive patient had con-
verted from seropositive to seronegative (data not
shown), while 35% of E7 positive patients had converted
from seropositive to seronegative (Kappas for agreement
= 0.8-0.97). The two seronegative patients who displayed
a conversion to seropositivity between BL and FU1 were
seronegative at FU2 (OD ratios: BL = 0.46, FU1 = 1.1,
FU2 = 0.74 and BL = 0.54, FU1 = 2.0, FU2 = 0.46).
The independent effects of treatment and E6/E7 anti-
body levels could not be assessed because treatment,
tumor site, and seropositives t a t u sw e r eh i g h l yc o r r e -
lated with one another. Treatment was significantly dif-
ferent by tumor site (p < 0.0001, data not shown). Over
95% of OC cases and 89% of LH cases had surgery,
w h i l eo n l y3 3 %o fO Pc a s e sd i d .C h e m o t h e r a p yw a s
administered in 59% of OP patients, 1% of OC cases,
and no LH cancer patients. In contrast, 89% of OP
tumors had radiation compared to 47% of OC and 44%
of LH tumors. However, 77% of the seropositive patients
also had OP tumors, while only 15% of OC and 8% of
LH tumors were seropositive.
Approximately 86% of all seropositive BL E6 patients
and 85% of BL E7 had radiation therapy. Among all BL
E6 seropositive patients whose OD ratio decreased, 94%
had radiation therapy alone or with surgery and/or che-
motherapy, whereas only 67% of patients with no
changes in OD values had similar treatment regimens (p
= 0.17, data not shown). Among all HPV seropositive
BL E7 patients, 85% of those who decreased and 85% of
those with no change, had radiation therapy. There was
no association between those who decreased and those
whose OD ratios remained unchanged among patients
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Page 3 of 9Table 1 Risk factors and histopathologic characteristics of HNC cases (N = 109)
1 by baseline HPV-16 E6/E7 status
Characteristics HPV-16 E6
2 Adjusted OR
5 HPV-16 E7
3 Adjusted
OR
5
HPV-16 E6 and/or E7
4 Adjusted
OR
5
Positive n
(%)
Negative
n (%)
Positive n
(%)
Negative
n (%)
Positive n
(%)
Negative
n (%)
Gender
Male 15 (68.2) 52 (59.8) 3.0 (0.9-9.4) 15 (75.0) 52 (58.4) 3.4 (1.01-
11.5)
17 (65.4) 50 (60.2) 1.9 (0.7-5.2)
Female 7 (31.8) 35 (40.2) 1.0 5 (25.0) 37 (41.6) 1.0 9 (34.6) 33 (39.8) 1.0
Age Group
≤ 55 years 14 (63.6) 30 (34.5) 2.7 (0.96-7.7) 12 (60.0) 32 (36.0) 2.7 (0.9-7.6) 15 (57.7) 29 (34.9) 2.5 (0.97-6.6)
> 55 years 8 (36.4) 57 (65.5) 1.0 8 (40.0) 57 (64.0) 1.0 11 (42.3) 54 (65.1) 1.0
Number of Partners
0-2 7 (33.3) 35 (43.7) 1.0 6 (33.3) 36 (43.4) 1.0 9 (37.5) 33 (42.9) 1.0
3-9 5 (23.8) 23 (28.8) 1.4 (0.4-5.7) 4 (22.2) 24 (28.9) 1.3 (0.3-5.6) 5 (20.8) 23 (29.9) 1.0 (0.3-3.6)
≥ 10 9 (42.9) 22 (27.5) 6.9 (1.5-33.2) 8 (44.4) 23 (27.7) 5.6 (1.2-26.5) 10 (41.7) 21 (27.3) 4.5 (1.1-18.6)
Pack years
Never 6 (27.3) 23 (26.4) 1.0 4 (20.0) 25 (28.1) 1.0 6 (23.1) 23 (27.7) 1.0
≤ 30 12 (54.5) 14 (16.1) 4.0 (1.1-14.1) 10 (50.0) 16 (18.0) 4.6 (1.2-18.3) 12 (46.2) 14 (16.9) 4.1 (1.2-14.3)
> 30 4 (18.2) 50 (57.5) 0.4 (0.1-1.8) 6 (30.0) 48 (53.9) 1.1 (0.2-4.7) 8 (30.8) 46 (55.4) 1.0 (0.3-3.5)
Drinks per Week
Never 6 (27.3) 28 (32.2) 1.0 5 (25.0) 29 (32.6) 1.0 7 (26.9) 27 (32.5) 1.0
≤ 21 10 (45.5) 34 (39.1) 2.0 (0.6-6.6) 9 (45.0) 35 (39.3) 1.8 (0.5-6.1) 12 (46.2) 32 (38.6) 1.7 (0.6-5.2)
> 21 6 (27.3) 25 (28.7) 3.7 (0.8-18.1) 6 (30.0) 25 (28.1) 2.5 (0.6-11.3) 7 (26.9) 24 (28.9) 2.0 (0.5-7.8)
Tumor Site
Oropharynx 20 (90.9) 7 (8.1) 51.9
(2.7-1007.0)
6
16 (80.0) 11 (12.4) 4.1 (0.5-32.6) 20 (76.9) 7 (8.4) 7.9 (1.04-
60.8)
Oral Cavity 2 (9.1) 71 (81.6) 0.7 (0.03-14.9)
6 2 (10.0) 71 (79.8) 0.1
(0.01-0.7)
6
4 (15.4) 69 (83.1) 0.2
(0.02-1.2)
6
Larynx
\hypopharynx
0 (0.0) 9 (10.3) 1.0 2 (10.0) 7 (7.9) 1.0 2 (7.7) 7 (8.4) 1.0
Oropharynx vs. Oral
Cavity
19.7 (5.3-73.9)
7 10.1
(2.9-35.8)
7
24.2
(1.5-384.0)
7
Stage
I/II 2 (9.1) 38 (43.7) 1.0 1 (5.0) 39 (43.8) 1.0 3 (11.5) 37 (44.6) 1.0
III/IV 20 (90.9) 49 (56.3) 23.7 (4.2-133.6) 19 (95.0) 50 (56.2) 26.2
(3.1-221.8)
23 (88.5) 46 (55.4) 11.3
(2.8-45.8)
Tumor Size
T0-T2 18 (81.8) 45 (52.9) 1.0 13 (65.0) 50 (57.5) 1.0 19 (73.1) 44 (54.3) 1.0
T3-T4 4 (18.2) 40 (47.1) 0.3 (0.1-1.04) 7 (35.0) 37 (42.5) 0.9 (0.3-2.6) 7 (26.9) 37 (45.7) 0.5 (0.2-1.4)
Grade
Poor/
Undifferentiated
11 (50.0) 14 (16.1) 5.5 (1.8-17.1) 9 (45.0) 16 (18.0) 3.7 (1.3-11.1) 12 (46.2) 13 (15.7) 4.8 (1.7-13.7)
Well/Moderate 11 (50.0) 73 (83.9) 1.0 11 (55.0) 73 (82.0) 1.0 14 (53.8) 70 (84.3) 1.0
Nodal Involvement
Yes 20 (90.9) 31 (35.6) 37.3 (6.8-204.3) 17 (85.0) 34 (38.2) 11.3
(2.8-45.1)
21 (80.8) 30 (36.1) 9.4 (2.9-30.0)
No 2 (9.1) 56 (64.4) 1.0 3 (15.0) 55 (61.8) 1.0 5 (19.2) 53 (63.9) 1.0
HPV DNA
High-Risk 20 (90.9) 10 (11.5) 22.0 (6.2-77.2)
7 16 (80.0) 14 (15.7) 27.8
(7.2-107.8)
21 (80.8) 9 (10.8) 60.1
(13.9-259.4)
Type 16 19 (90.5) 9 (10.5) 25.1
(6.6,-95.2)
7
16 (80.0) 12 (13.9) 32.5
(8.2-129.6)
20 (80.0) 8 (9.0) 58.0
(13.7-246.3)
Type 33 1 (0.4) 1 (1.0) NE 0 (0.0) 2 (1.8) NE 1 (0.8) 1 (1.8) NE
Negative 2 (9.1) 77 (88.5) 1.0 4 (20.0) 75 (84.3) 1.0 5 (19.2) 74 (89.2) 1.0
1Number of patients; percentages (%) based on available data;
2Cases seropositive for HPV-16 E6 compared to cases seronegative for HPV-16 E6;
3Cases
seropositive for HPV-16 E7 compared to cases seronegative for HPV-16 E7;
4Cases positive for E6 and/or E7 compared to cases negative for E6 and E7;
5Adjusted
for continuous age, continuous pack years, and continuous drinks per week;
6Unadjusted logit estimator of OR;
7Logit estimator of OR and 95% CI., adjusted for
categorical age, categorical pack years, and categorical drinks per week.
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ciation between treatment type and conversion from
HPV seropositive to seronegative at last FU.
Table 4 displays the HRs (CIs) for OS, DS, and recur-
rence free survival between BL and last FU, comparing
BL HPV seropositive to BL seronegative patients. The
percent that died or had a recurrence as well as the
change in OD ratios for these patients are also shown.
There were too few deaths in BL seropositive patients to
compare those with and without OD ratio reduction.
OS included 109 patients, DS 98 patients, and recur-
rence free survival 101 patients. Among those who did
not survive, 35% (n = 38) died from all causes com-
bined, 19% (19) from HNC, and 19% (19) had a recur-
rence. Median follow-up time for OS was 6.2 years
(range 0.5 to 9.1), for DS survival 6.4 years (range: 0.5
to 9.1), and for recurrence free survival 6.2 years (range:
0.3 to 9.1 years). For patients with a first recurrence,
Table 2 Baseline HPV-16 E6/E7 median OD
1 ratios
2 and ranges by risk factors, and histopathologic characteristics
Characteristics HPV-16 E6 HPV-16 E7 HPV-16 E6 and/or E7
Positive (n = 22) Positive (n = 20) Positive (n = 26)
n (%) Median (Range) n (%) Median (Range) n (%) Median (Range)
Gender
Male 15 (22.4) 5.2 (1.8-11.3) 15 (22.4) 5.5 (1.3-37.2) 17 (25.4) 5.9 (1.3-37.2)
Female 7 (16.7) 4.7 (1.2-5.7) 5 (11.9) 2.1 (1.01-14.7) 9 (21.4) 4.7 (1.2-14.7)
Age Group
≤ 55 years 14 (31.8) 5.3 (1.2-10.8) 12 (27.3) 4.9 (1.01-37.2) 15 (34.1) 5.5 (4.2-37.2)
> 55 years 8 (12.3) 5.0 (1.8-11.3) 8 (12.3) 5.7 (1.3-14.7) 11 (16.9) 5.8 (1.2-14.7)
Number of Partners
0-2 7 (16.7) 4.7 (1.2-7.3) 6 (14.3) 1.8 (1.01-37.2) 9 (21.4) 4.6 (1.2-37.2)
3-9 5 (17.9) 5.9 (1.8-9.0) 4 (14.3) 4.9 (3.8-11.0) 5 (17.9) 7.3 (5.2-11.0)
≥ 10 9 (29.0) 5.0 (2.5-11.3) 8 (25.8) 5.5 (1.5-9.3) 10 (32.3) 5.6 (4.2-11.3)
Pack years
Never 6 (20.7) 5.0 (1.2-9.0) 4 (13.8) 5.0 (3.8-9.3) 6 (20.7) 5.6 (1.2-9.3)
≤ 30 12 (46.2) 5.1 (2.5-10.8) 10 (38.5) 5.5 (1.01-37.2) 12 (46.2) 5.7 (4.3-37.2)
> 30 4 (7.4) 5.3 (1.8-11.3) 6 (11.1) 6.8 (1.3-14.7) 8 (14.8) 5.3 (1.3-14.7)
Drinks per Week
Never 6 (17.6) 5.1 (1.2-7.8) 5 (14.7) 6.1 (1.3-9.3) 7 (20.6) 5.9 (1.2-9.3)
≤ 21 10 (22.7) 5.3 (2.5-10.8) 9 (20.5) 4.3 (1.01-37.2) 12 (27.3) 5.6 (2.1-37.2)
> 21 6 (19.4) 4.7 (1.8-11.3) 6 (19.4) 5.0 (1.5-11.0) 7 (22.6) 5.2 (4.2-11.3)
Tumor Site
Oropharynx 20 (74.1) 5.1 (1.8-11.3) 16 (59.3) 5.7 (1.01-37.2) 20 (74.1) 5.9 (4.3-37.2)
Oral Cavity 2 (2.7) 2.6 (1.2-4.1)
3 2 (2.7) 9.5 (4.2-14.7)
3 4 (5.5) 4.2 (1.2-14.7)
Larynx\hypopharynx 0 (0.0) - 2 (22.2) 1.7 (1.3-2.1)
3 2 (22.2) 1.7 (1.3-2.1)
3
Stage
I/II 2 (5.0) 2.6 (1.2-4.1)
3 1 (2.5) 1.3 (1.3-1.3)
3 3 (7.5) 1.3 (1.2-4.1)*
III/IV 20 (29.0) 5.1 (1.8-11.3) 19 (27.5) 5.5 (1.01-37.2) 23 (33.3) 5.8 (2.1-37.2)*
Tumor Size
T0-T2 18 (28.6) 4.9 (1.2-11.3)* 13 (20.6) 5.5 (1.01-37.2) 19 (30.2) 5.5 (1.2-37.2)
T3-T4 4 (9.1) 6.8 (5.2-10.8)* 7 (15.9) 5.5 (2.1-14.7) 7 (15.9) 5.9 (2.1-14.7)
Grade
Poor/Undifferentiated 11 (44.0) 5.7 (4.2-11.3) 9 (36) 5.8 (1.01-37.2) 12 (48.0) 5.9 (1.3-37.2)
Well/Moderate 11 (13.1) 5.0 (1.2-10.8) 11 (13.1) 5.5 (1.6-14.7) 14 (16.7) 5.2 (1.2-14.7)
Nodal Involvement
Yes 20 (39.2) 5.1 (1.8-11.3) 17 (33.3) 5.5 (1.01-37.2) 21 (41.2) 5.8 (4.2-37.2)*
No 2 (3.5) 2.6 (1.2-4.1)
3 3 (5.2) 2.1 (1.3-14.7) 5 (8.6) 2.1 (1.2-14.7)*
HPV DNA
High-Risk 20 (66.7) 5.0 (1.2-11.3) 16 (53.3) 5.7 (1.01-37.2) 21 (70.0) 5.7 (1.2-37.2)
Negative 2 (2.5) 7.1 (5.2-9.0) 4 (5.1) 3.0 (1.3-14.7) 5 (6.3) 5.2 (1.3-14.7)
1OD = optical density;
2All OD ratio tests were two-group comparisons: reference for partners was 0-2, reference for alcohol and tobacco was ‘never’, reference
for tumor site was ‘oropharynx’;
3Mean and range; *p-value for median difference between groups was ≤ 0.05.
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Page 5 of 984% occurred less than 20 months after diagnosis. For
OS, 40% of the BL E6 seronegative vs. 14% of the BL E6
seropositive patients died (HR: 4.6); 38% of the BL E7
seronegative vs. 20% of the BL E7 seropositive did not
survive (HR: 3.0); and 41% of the seronegative vs. 15%
of the seropositive BL E6 and/or E7 died (HR: 3.8).
Figures 1, 2, and 3 display the DS survival differences in
seronegative and seropositive patients by BL E6, E7, and
E6 and/or E7 status, respectively. DS death was 23%-
24% among BL seronegative patients whereas there were
no DS deaths among BL E6 positive patients (p = 0.01),
one death among BL E7 positive patients (HR: 6.4) and
one death among the BL E6 and/or E7 seropositive
patients (HR: 8.4). There were no significant differences
in recurrence between HPV BL seronegative and BL ser-
opositive patients.
When compared by HPV-HR tumor positive vs. nega-
tive status (data not shown), the mortality rate for OS
were 27% vs. 38% (HR: 2.1, 0.9-4.6, p = 0.07), for DS
deaths, 12% vs. 22% (HR: 2.6, 0.7-9.0, p = 0.14) and for
recurrence, 14% vs. 21% (HR: 1.5, 0.5-4.6, p = 0.49). The
patient who was BL E6 and/or E7 seronegative and
HPV-33 tumor positive died from HNC (survival time =
1.8 years) and also had a recurrence (time to recurrence
= 1.2 years). The patient who was BL E6 and/or E7
positive and HPV-33 tumor positive was alive and dis-
ease free at last contact (follow-up time = 6.3 years). Of
the 5 E6 and/or E7 seropositive patients who were HPV
tumor negative, none had died (mean (SE) follow-up
time = 5.4 (0.7) years, range 3.1-7.4 years) and one had
a recurrence at 20 months.
Discussion
This is the first study to describe the association
between risk factors, pathological characteristics, and
HNC survival with specific anti-HPV antibody levels at
Table 3 Change
1 in seropositive OD ratios between
baseline (BL) and follow-up (FU)
2 for BL seropositive
cases
Change
1 in OD Ratio HPV-16 E6 N = 22 HPV-16 E7
n=2 0
n (%) n (%)
BL to FU1
No decrease 8 (36.6) 10 (50.0)
Decrease 14 (63.4) 10 (50.0)
p-value
3 0.10 0.50
BL to FU2
No decrease 3 (25.0) 4 (36.4)
Decrease 9 (75.0) 7 (63.6)
p-value
3 0.04 0.19
BL to last FU
No decrease 6 (27.3) 7 (35.0)
Decrease 16 (72.7) 13 (65.0)
p-value
3 0.02 0.09
1Based on ≥ 2-fold titration change using the last titration at each follow-up.
2FU1 = follow-up 1, FU2 = follow-up 2, FU = last follow-up,
3One-sided p-
values for the binomial test that the proportion of patients who decreased
was > 0.50.
Table 4 Hazard Ratios by HPV-16 E6/E7 baseline status and change in OD ratio at last follow-up
Outcome/Antibody Status HPV-16 E6 HPV-16 E7 HPV-16 E6 and/or E7
n (%) HR (95% CI)
1 p-value
2 n (%) HR (95% CI)
1 p-value
2 n (%) HR (95% CI)
1 p-value
2
Overall Deaths 0.01 0.04 0.01
Negative 35
3 (40.2) 4.6 (1.4-15.3) 34
4 (38.2) 3.0 (1.03-8.5) 34
4 (41.0) 3.8 (1.3-11.0)
Positive 3 (13.6) 1.0 4 (20.0) 1.0 4 (15.8) 1.0
No OD decrease 0 0 0
OD Decrease 3
5 4
5 4
5
Disease Specific Deaths 0.01
7 0.07 0.04
Negative 19
6 (24.4) NE
3 18
8 (22.5) 6.4 (0.8-48.7) 18
8 (24.3) 8.4 (1.1-63.3)
Positive 0 (0.0) 1.0 1 (5.6) 1.0 1 (4.2) 1.0
No OD decrease 0 0 0
OD Decrease 0 1
5 1
5
Recurrence 0.35 0.36 0.90
Negative 17
8 (21.5) 2.1 (0.4-9.7) 17
4 (21.0) 2.0 (0.4-9.4) 15
9 (20.0) 1.1 (0.3-3.5)
Positive 2 (9.1) 1.0 2 (10.0) 1.0 4 (15.4) 1.0
No OD decrease 1
5 02
5
OD Decrease 1 2
10 2
10
1Adjusted for continuous age and stage;
2Adjusted p-value from Cox Regression models;
3Tumor status: 3 HPV-16, 1 HPV-33, 27 HPV-;
4Tumor status: 2 HPV-16, 1
HPV-33, 27 HPV-;
5Tumor status: all HPV-16;
6Tumor status: 2 HPV-16, 18 HPV-;
7Not estimable, Kaplan-Meier log-rank p = 0.01;
8Tumor status: 1 HPV-16, 1 HPV-33,
14 HPV-;
9Tumor status: 1 HPV-33, 13 HPV-;
10Tumor status: 1 HPV-16, 1 HPV-.
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in cervical cancer studies [13,29,30,14]. The purpose for
evaluating OD values at FUP in association with treat-
ment was to determine whether treatment had an effect
on OD levels. In cervical cancer, following OD levels
over time after treatment has shown both an increase in
survival and lower recurrence in those whose OD levels
decreased. In this study, we found that median OD
values for HPV-16 E6 and/or E7 antibodies at baseline
were not consistently associated with risk factors for
HNC. In contrast, between BL and the last FU, there
was a statistically significant reduction in E6 antibodies
and a non-significant decrease in E7 antibodies. In addi-
tion, overall and disease specific survival were better
among the BL E6 and/or E7 seropositive patients com-
pared to seronegative patients, reflecting significantly
lower mortality in patients with BL E6 antibodies and
also (non-statistically significant) lower mortality in
patients with BL E7 antibodies.
Although there are no large studies of HPV antibody
levels in HNC prior to and following treatment, studies
of cervical cancer have examined pre/post-treatment
titers for associations with risk factors, tumor character-
istics, and clinical outcomes [13,29,30,14] and may pro-
vide a model for comparison. Cervical cancer research
has suggested that decreases in E6 or E7 antibody levels
between pre-and post-treatment were associated with
continuing remission [13,29,30,14]. In contrast, persis-
tent or increasing antibody levels showed evidence for
continuing or recurrent disease [29,30,14]. Hamšíková et
al. [14] found decreases in E7 antibody levels after radia-
tion treatment of advanced cervical cancer cases. Fisher
et al. [30] observed significant decreases in both HPV-
16 E6 and E7 levels after radiation treatment. Baay et al.
[19,13] reported similar findings but did not distinguish
changes by treatment. Di Lonardo et al. [29] found no
decrease in serum E7 levels for cervical cancer patients
in stages IIB and IIIB three months after chemotherapy,
but did observe a significant E7 OD decrease in 90% of
the women after surgery regardless of tumor stage and
prior chemotherapy.
In this HNC study, 73% of BL E6 positive and 65% of
BL E7 positive patients exhibited decreases in OD levels
with 85%-94% of those with a decrease also receiving
radiation treatment alone or in combination with other
therapies. These treatment rates reflected the high corre-
lation between seropositivity and OP cancer and serone-
gativity and OC cancer. Eighty percent of stage III/IV E6
Figure 1 Disease specific survival by HPV-16 E6 status. Survival
curves based on the Kaplan-Meier method. Significance was based
on the Log-rank comparisons of positive vs. negative status, p =
0.02.
Figure 2 Disease specific survival by HPV-16 E7 status. Survival
curves based on the Kaplan-Meier method. Significance was based
on the Log-rank comparisons of positive vs. negative status, p =
0.11.
Figure 3 Disease specific survival by HPV-16 E6 and/or E7
status. Survival curves based on the Kaplan-Meier method.
Significance was based on the Log-rank comparisons of positive vs.
negative status, p = 0.04.
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exhibited decreases in their OD ratios. The decline in E6
and/or E7 antibodies after tumor removal or radiation
suggest that these viral oncoproteins play a role in tumor
genesis and growth in patients infected with HPV-HR.
Identifying the metabolic pathway of these oncoproteins
may indicate new targets for more effective therapies.
E6 and/or E7 prevalence rates at baseline and at the
last FU in our HNC cases were difficult to compare to
the prevalence rates in the study by Zumbach et al. [7]
because the distribution of tumors was very different by
site and it is well-established that OP cases are more
likely to be HPV positive [8]. Over 65% of the Iowa
tumors were from the OC, 25% from the OP, and 8%
from the LH. In the German study, the proportions
were approximately 4%, 37%, and 49%, respectively. In
addition, Zumbach compared two different groups of
patients, one with sera collected around the time of
diagnosis and another with sera collected 6-26 month
after diagnosis and treatment.
Conclusions
Serology tests of HPV titer levels performed at pre-and
post-treatment provide useful markers of clinical out-
comes of cervical cancer. HNC serologic assessment of
HPV E6 and E7 antibody changes may be a useful clini-
cal method for monitoring patient treatment response
and early warning of recurrence. Further investigation of
changes in OD levels in HPV-associated head and neck
tumors needs to be performed
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